Answers are grounded in this paper and cite their sources.
Multicenter study reveals effectiveness of ranibizumab plus PRP in patients with PDR, suggesting new treatment pathways.
Proliferative diabetic retinopathy (PDR) is one of the main causes of vision loss in diabetes mellitus. Panretinal laser photocoagulation (PRP) remains one of the main methods of treating the proliferative process in diabetic retinal damage. In 2018, a prospective randomized multicenter open-label PROTEUS study demonstrated higher efficacy of PRP in combination with intravitreal ranibizumab compared to PRP alone in the treatment of patients with high-risk PDR. This article presents three clinical cases of combination therapy for proliferative diabetic retinopathy using a Russian biosimilar of ranibizumab in patients with type 1 diabetes mellitus.
No takes yet. Share an insight, caveat, or question.
Малахова et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: